Pharmacies & Drug Stores in European Union 2026: Industry Statistics & Trends

The pharmacies and drug stores industry in the European Union comprises specialized retail outlets dedicated to dispensing prescription medications, over-the-counter drugs, and healthcare products. The sector is moving toward broader clinical service provisioning, though it remains under significant operational pressure due to systemic supply chain challenges. According to the Pharmaceutical Group of the European Union (PGEU) Medicines Shortages Report 2025, medicine shortages persisted in 96% of responding member countries during the 2025 survey period, with community pharmacies spending an average of 12 hours per week managing these supply shortfalls. Concurrently, broader non-food retail

Industry snapshot

Key public data points

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Pharmacies & Drug Stores in European Union industry cover?

The industry comprises the specialized retail sale of pharmaceutical and medicinal products to the general public. Establishions in this sector are primarily focused on dispensing prescription-only medicines (POM), pharmacy-only medicines, and over-the-counter (OTC) drugs. Scope boundaries exclude medical wholesaling and the distribution of medical equipment to institutional buyers like hospitals.

• •Classified officially under NACE Rev. 2 code 47.73 for the retail sale of pharmaceuticals in specialized stores.
• •Includes secondary product lines such as homeopathic remedies, medical devices, and personal hygiene products.
• •Excludes general supermarkets or online-only non-pharmacy retailers that do not employ licensed pharmacists for dispensing.

Who operates in the industry and how is it structured?

The European pharmacy market structure is highly fragmented and varies dramatically by member state due to differing national legislation on ownership. Several EU countries enforce strict 'pro-pharmacist' ownership laws that ban corporate pharmacy chains, while others allow fully liberalized vertical integration. This creates a dual landscape of independent single-unit pharmacies alongside large corporate pan-European networks.

• •Countries like Germany, France, and Spain legally restrict pharmacy ownership exclusively to registered pharmacists.
• •Countries like Sweden, the Netherlands, and Lithuania operate under liberalized regimes permitting corporate chain ownership.
• •Independent pharmacies frequently join buying groups or voluntary marketing alliances to achieve economies of scale.

What drives demand in the industry?

Demand within the EU pharmacy sector is driven primarily by secular demographic shifts and the expanding healthcare needs of an aging population. The rising prevalence of chronic conditions requires ongoing pharmaceutical therapeutic intervention, generating a consistent baseline of prescription volumes. Furthermore, consumer interest in preventative healthcare and wellness supports sales of premium OTC and cosmetic product lines.

• •A growing elderly demographic across the EU accelerates the consumption of cardiovascular, metabolic, and oncology treatments.
• •Public health initiatives increasingly offload minor ailment management from primary care physicians to community pharmacies.
• •Fluctuations in seasonal illnesses, such as respiratory infections, create predictable surges in OTC cough, cold, and antiviral demand.

Who are the notable companies in the industry?

Competition manifests differently across the EU based on regional regulatory allowances for corporate retail footprints. In liberalized jurisdictions, large multinational healthcare distributors and dedicated retail chains dominate market share and compete heavily on digital accessibility and loyalty frameworks. Conversely, in protected markets, competition is localized and focuses heavily on patient proximity and professional consulting services.

• •Celesio (operating widely under the LloydsPharmacy brand historically, part of the McKesson Europe ecosystem) maintains a prominent retail presence.
• •Phoenix Pharmahandel / PHOENIX Group operates extensive retail pharmacy networks across multiple European countries including the BENELUX and Baltic regions.
• •Boots (a subsidiary of Walgreens Boots Alliance) operates corporate retail drugstores and pharmacy counters within the Republic of Ireland and formerly across broader European footprints.
• •CECOFAR and Cofares operate as massive pharmaceutical distribution cooperatives supporting competitive independent retail operations in Southern Europe.

What are the recent trends and outlook?

The contemporary industry outlook is defined by structural supply chain volatility and a rapid pivot toward digital integration. Pharmacists are forced to dedicate substantial administrative hours to sourcing alternative therapies amid widespread stock exclusions. Concurrently, the legislative adoption of electronic prescriptions (e-prescriptions) across EU member states is standardizing digital fulfillment and paving the way for hybrid click-and-collect models.

• •The PGEU 2025 survey highlights that 89% of responding countries reported treatment interruptions due to ongoing drug shortages.
• •Only 15% of EU countries currently allow full therapeutic substitution by pharmacists without formal protocol amendments.
• •Digital health infrastructure spending is rising as pharmacies integrate national health insurance telematics systems.

How is the industry regulated?

The industry operates under strict oversight divided between European Union directives and sovereign national healthcare mandates. National regulatory bodies control retail pharmacy licensing, geographic zoning rules, and product pricing or reimbursement rates under public insurance schemes. European-level legislation focuses primarily on supply chain safety, product integrity, and standardizing medical data transfers.

• •Adherence to the EU Falsified Medicines Directive (Directive 2011/62/EU) requires end-to-end verification via unique identifiers on medicine packaging.
• •National regulatory frameworks dictate the 'External Price Referencing' (EPR) systems that directly compress pharmacy retail margins on reimbursed drugs.
• •Compliance with the General Data Protection Regulation (GDPR) governs how pharmacies collect, process, and store sensitive patient health records.

Government, statistical and trade sources used for this Claight analysis.

• Eurostat / Hungarian Central Statistical Office (HCSO) Volume Change in Retail Trade in the Member States of the European Union, March 2025 Edition ·
• Pharmaceutical Group of the European Union (PGEU) Medicine Shortages Report 2025 ·
• European Commission NACE Rev. 2 Statistical Classification of Economic Activities